Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
05
2019
accepted:
22
10
2019
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
25
3
2020
Statut:
epublish
Résumé
MiR-33a has emerged as a critical regulator of lipid homeostasis in the liver. Genetic deficiency of miR-33a aggravates liver steatosis in a preclinical model of non-alcoholic fatty liver disease (NAFLD), and relative expression of miR-33a is increased in the livers of patients with non-alcoholic steatohepatitis (NASH). It was unknown whether miR-33a is detectable in the serum of patients with NAFLD. We sought to determine whether circulating miR-33a is associated with histological hepatic steatosis, inflammation, ballooning or fibrosis, and whether it could be used as a serum marker in patients with NAFLD/NASH. We analysed circulating miR-33a using quantitative PCR in 116 liver transplant recipients who underwent post-transplant protocol liver biopsy. Regression analysis was used to determine association of serum miR-33a with hepatic steatosis, inflammation, ballooning and fibrosis in liver biopsy. Liver graft steatosis and inflammation, but not ballooning or fibrosis, were significantly associated with serum miR-33a, dyslipidemia and insulin resistance markers on univariate analysis. Multivariate analysis showed that steatosis was independently associated with serum miR-33a, ALT, glycaemia and waist circumference, whereas inflammation was independently associated with miR-33a, HbA1 and serum triglyceride levels. Receiver operating characteristic analysis showed that exclusion of serum miR-33a from multivariate analysis resulted in non-significant reduction of prediction model accuracy of liver steatosis or inflammation. Our data indicate that circulating miR-33a is an independent predictor of liver steatosis and inflammation in patients after liver transplantation. Although statistically significant, its contribution to the accuracy of prediction model employing readily available clinical and biochemical variables was limited in our cohort.
Sections du résumé
BACKGROUND & AIMS
MiR-33a has emerged as a critical regulator of lipid homeostasis in the liver. Genetic deficiency of miR-33a aggravates liver steatosis in a preclinical model of non-alcoholic fatty liver disease (NAFLD), and relative expression of miR-33a is increased in the livers of patients with non-alcoholic steatohepatitis (NASH). It was unknown whether miR-33a is detectable in the serum of patients with NAFLD. We sought to determine whether circulating miR-33a is associated with histological hepatic steatosis, inflammation, ballooning or fibrosis, and whether it could be used as a serum marker in patients with NAFLD/NASH.
METHODS
We analysed circulating miR-33a using quantitative PCR in 116 liver transplant recipients who underwent post-transplant protocol liver biopsy. Regression analysis was used to determine association of serum miR-33a with hepatic steatosis, inflammation, ballooning and fibrosis in liver biopsy.
RESULTS
Liver graft steatosis and inflammation, but not ballooning or fibrosis, were significantly associated with serum miR-33a, dyslipidemia and insulin resistance markers on univariate analysis. Multivariate analysis showed that steatosis was independently associated with serum miR-33a, ALT, glycaemia and waist circumference, whereas inflammation was independently associated with miR-33a, HbA1 and serum triglyceride levels. Receiver operating characteristic analysis showed that exclusion of serum miR-33a from multivariate analysis resulted in non-significant reduction of prediction model accuracy of liver steatosis or inflammation.
CONCLUSIONS
Our data indicate that circulating miR-33a is an independent predictor of liver steatosis and inflammation in patients after liver transplantation. Although statistically significant, its contribution to the accuracy of prediction model employing readily available clinical and biochemical variables was limited in our cohort.
Identifiants
pubmed: 31703079
doi: 10.1371/journal.pone.0224820
pii: PONE-D-19-13024
pmc: PMC6839850
doi:
Substances chimiques
Biomarkers
0
Circulating MicroRNA
0
MIRN33a microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224820Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Liver Transpl. 2016 May;22(5):644-55
pubmed: 26707008
N Engl J Med. 2018 Feb 22;378(8):781
pubmed: 29466150
Dig Liver Dis. 2018 May;50(5):490-495
pubmed: 29396131
Nature. 2011 Oct 19;478(7369):404-7
pubmed: 22012398
Transplantation. 2019 Jul 26;:null
pubmed: 31356578
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Am J Gastroenterol. 2010 Mar;105(3):613-20
pubmed: 20040915
Liver Int. 2016 Sep;36(9):1383-91
pubmed: 26945479
J Hepatol. 2018 Dec;69(6):1335-1348
pubmed: 30142428
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):239-50
pubmed: 22436747
Science. 2010 Jun 18;328(5985):1570-3
pubmed: 20466885
Transplantation. 2019 Jan;103(1):e14-e21
pubmed: 29994981
Transplant Proc. 2009 Nov;41(9):3560-3
pubmed: 19917344
J Clin Invest. 2002 May;109(9):1125-31
pubmed: 11994399
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Science. 2011 Jun 24;332(6037):1519-23
pubmed: 21700865
Sci Rep. 2018 Jul 13;8(1):10606
pubmed: 30006517
Transplantation. 1996 Nov 15;62(9):1246-51
pubmed: 8932265
Science. 2010 Jun 18;328(5985):1566-9
pubmed: 20466882
Ann Surg. 2007 Dec;246(6):940-6; discussion 946-8
pubmed: 18043095
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):542-52
pubmed: 23689081
Transplantation. 2019 Jan;103(1):22-27
pubmed: 30335697
Nat Commun. 2013;4:2883
pubmed: 24300912